



Patent Application

17

THE UNITED STATES PATENT AND TRADEMARK OFFICE

For: NOVEL VACCINE COMPOSITION AND USE OF SURFACTANTS AS ADJUVANTS OF IMMUNITY

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Director of the United States
Patent and Trademark Office
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicant respectfully requests consideration of the references listed on the attached Form PTO/SB/08A. Copies of the references listed are also enclosed.

Applicant respectfully requests that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.


Applicants' submission of this Information Disclosure Statement (IDS) shall not be construed as an admission that the cited references are prior art to the present invention, or that the cited references qualify as printed publications. The submission of this IDS also shall not be construed as a representation that a prior art search has been performed.

This IDS is submitted prior to the issuance of a first Office Action on the merits;

therefore, it is believed that no fees are required in connection therewith. If any fees are necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

By:


Robert M. Schulman
Registration No. 31,196

Dated: November 4, 2002

Hunton & Williams
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

David H. Milligan
Registration No. 42,893